Ampio Pharmaceuticals EBITDA | AMPE

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Ampio Pharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
122 K	1.05 M	1.09 M	1.18 M	1.27 M	1.28 M	1.21 M	1.21 M	-32.5 M	-38.7 M	-23.9 M	62.4 K	42.6 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.28 M	-38.7 M	-6.66 M

Quarterly EBITDA Ampio Pharmaceuticals

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
122 K	122 K	122 K	-	865 K	518 K	262 K	-	831 K	568 K	294 K	-	885 K	591 K	295 K	-	975 K	736 K	365 K	-	968 K	621 K	301 K	-	911 K	607 K	304 K	-	917 K	611 K	306 K	-	-6.86 M	462 K	231 K	-	-9.29 M	83.1 K	41.2 K	-	97.3 K	57.8 K	18.5 K	-	46.8 K	31.2 K	15.6 K	-	27 K	11.4 K	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
975 K	-9.29 M	-50.7 K

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Завод ДИОД DIOD	85.9 M	-	-	-	Russia
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Cleveland BioLabs, Inc. CBLI	-2.58 M	-	-7.31 %	$ 49 M	USA
Five Prime Therapeutics, Inc. FPRX	-87 M	-	-	$ 1.77 B	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	-620 M	-	-6.81 %	$ 3.04 B	USA
Biofrontera AG BFRA	-2.28 M	-	-8.24 %	$ 105 M	Germany
Catabasis Pharmaceuticals, Inc. CATB	-37.4 M	-	-6.97 %	$ 657 M	USA
China Biologic Products Holdings, Inc. CBPO	223 M	-	1.68 %	$ 4.65 B	China
Flexion Therapeutics, Inc. FLXN	-89.7 M	-	-	$ 459 M	USA
Heat Biologics, Inc. HTBX	-24.7 M	-	-5.76 %	$ 99.8 M	USA
Kindred Biosciences, Inc. KIN	-11 M	-	0.11 %	$ 419 M	USA
Shineco, Inc. TYHT	-4.38 M	-	-3.90 %	$ 97.2 M	China
Intec Pharma Ltd NTEC	-12.6 M	-	-12.45 %	$ 17.7 M	Israel
Progenity, Inc. PROG	-190 M	-	-3.47 %	$ 164 M	USA
CTI BioPharma Corp. CTIC	-77.8 M	-	-	$ 1.2 B	USA
Strongbridge Biopharma plc SBBP	-38.1 M	-	1.52 %	$ 136 M	USA
Decibel Therapeutics DBTX	-62.5 M	-	-	$ 123 M	USA
Seneca Biopharma, Inc. SNCA	-10.6 M	-	-1.19 %	$ 28.7 M	USA
IVERIC bio ISEE	-190 M	-	-	$ 5.51 B	USA
Myovant Sciences Ltd. MYOV	-186 M	-	-0.04 %	$ 2.62 B	USA
Trean Insurance Group TIG	820 K	-	-	$ 316 M	USA
Virpax Pharmaceuticals VRPX	-12.1 M	-	-45.12 %	$ 2.85 M	USA
Metacrine MTCR	-60.8 M	-	-	$ 24.2 M	USA
Celsion Corporation CLSN	-14.4 M	-	-6.63 %	$ 13.9 M	USA
I-Mab IMAB	23.9 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
AnaptysBio ANAB	48.5 M	$ 56.8	0.94 %	$ 1.63 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-14.3 M	-	-13.47 %	$ 169 M	France
CureVac N.V. CVAC	178 M	-	-	$ 867 M	Germany
BiondVax Pharmaceuticals Ltd. BVXV	-11.9 M	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	-10.1 M	-	-	$ 4.9 B	Britain
Midatech Pharma plc MTP	-8.64 M	-	-18.52 %	$ 27.3 M	Britain
MorphoSys AG MOR	-252 M	-	2.43 %	$ 254 M	Germany
Affimed N.V. AFMD	-107 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	-100 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	-40.9 M	-	-	$ 12.5 M	Belgium
Gracell Biotechnologies GRCL	-566 M	-	-	$ 3.37 B	China
Galapagos NV GLPG	351 M	-	-	$ 1.83 B	Belgium
Teligent, Inc. TLGT	48.6 M	-	-13.85 %	$ 16.1 M	USA
Viela Bio, Inc. VIE	-151 M	-	-	$ 2.91 B	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Aphria Inc. APHA	-8.68 M	-	-0.45 %	$ 4.87 B	Canada
Aerpio Pharmaceuticals, Inc. ARPO	-6.22 M	-	-0.90 %	$ 104 M	USA